Corvus Pharmaceuticals reported highly positive data from cohort 4 of its Phase 1 trial of soquelitinib in moderate-to-severe atopic dermatitis. In the 200 mg twice-daily dosing arm, 75% of patients achieved at least a 75% improvement in Eczema Area and Severity Index (EASI 75) after eight weeks of treatment. Furthermore, 33% of participants reached clear or almost clear skin (Investigator’s Global Assessment 0/1). Importantly, these clinical benefits persisted one month after treatment cessation, indicating durable response.

Soquelitinib demonstrated a favorable safety profile, with no treatment-related serious adverse events reported in cohort 4. Most adverse events were low-grade laboratory abnormalities and transient mild gastrointestinal effects. Biomarker analyses showed dose-dependent reductions in Th2-associated cytokines and modulation of T-cell activation markers, supporting the drug’s targeted ITK-inhibitory mechanism and its potential to address treatment-resistant patients.

To capitalize on these encouraging data, Corvus launched a $150 million public offering of common stock and pre-funded warrants, with an underwriter option to raise an additional $22.5 million. The net proceeds are earmarked for pivotal Phase 2/3 atopic dermatitis studies, expansion into hidradenitis suppurativa and asthma trials, and general corporate purposes. This financing is expected to extend the company’s cash runway through key development milestones into late 2027.

Investors will be watching for initiation of randomized, placebo-controlled Phase 2 trials in atopic dermatitis, anticipated in second quarter 2026, and topline data expected by mid-2027. Additional readouts from ongoing PTCL and other immuno-oncology trials will further de-risk the program. Durability of response and comparative efficacy versus existing JAK inhibitors will be critical for establishing soquelitinib as a ‘best-in-class’ ITK inhibitor in immune-mediated skin diseases.